Exagen Inc reports results for the quarter ended in March - Earnings Summary

Exagen

13/05/2024 15:08

* Exagen Inc  XGN.OQ  reported a quarterly adjusted loss
of 19
cents​​ per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of -44
cents.  The mean expectation of six analysts for the quarter was
for a loss of 36 cents per share. Wall Street expected
results to range from -40 cents to -32 cents per share.
    * Revenue rose 28.4% to $14.42 million from a year ago;
analysts
expected $13.10 million. 
    * Exagen Inc's reported EPS for the quarter was a loss of 19
cents​.
    * The company reported a quarterly loss of $3.36 million.
    * Exagen Inc shares had fallen by 1.3% this quarter and
lost 21.1%
so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 13.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the healthcare
facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Exagen Inc is
$5.00 
This summary was machine generated from LSEG data May 13 at
02:08 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.36          -0.19          Beat
 Dec. 31 2023      -0.43          -0.31          Beat
 Sep. 30 2023      -0.47          -0.31          Beat
 Jun. 30 2023      -0.49          -0.28          Beat